Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $630.00 | Neutral | Mizuho |
| 11/7/2024 | $531.00 → $688.00 | Neutral → Outperform | Robert W. Baird |
| 9/24/2024 | $603.00 → $531.00 | Outperform → Neutral | Robert W. Baird |
| 9/5/2024 | $670.00 → $665.00 | Outperform | Leerink Partners |
| 8/8/2024 | $540.00 → $570.00 | Neutral | Mizuho |
| 2/26/2024 | $600.00 | Outperform | Leerink Partners |
| 1/3/2024 | $537.00 | Overweight | Barclays |
| 12/14/2023 | $502.00 | Equal Weight | Wells Fargo |
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal
McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he
McKesson Corporation (NYSE:MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson's leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company's strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along with the company's slide presentation will be available on McKesson's Investor Relations website at investor.mckesson.com, where you can find a complete listing of upcoming events, including details and updates. About McKesson Corporati
144 - MCKESSON CORP (0000927653) (Subject)
DEFA14A - MCKESSON CORP (0000927653) (Filer)
DEFA14A - MCKESSON CORP (0000927653) (Filer)
Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00
Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously
Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
4 - MCKESSON CORP (0000927653) (Issuer)
Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.82 per share of common stock, a 15% increase from $0.71 per share in the prior quarter. The dividend will be payable on October 1, 2025, to stockholders of record on September 2, 2025. "McKesson continues our long-standing track record of returning capital to shareholders, marking our ninth consecutive annual dividend increase," said Brian Tyler, chief executive officer. "These actions reflect our confidence in the strength of our business and reinforces our commitment to delivering long-term value to shareholders." About McKesson Corporation McKesson Corporation is a diversified heal
McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he
Strengthens Community-Based Oncology Care with Florida Cancer Specialists & Research Institute Core Ventures McKesson Corporation (NYSE:MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling intere
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)
SC 13G/A - MCKESSON CORP (0000927653) (Subject)